| Literature DB >> 26006224 |
Xueling Dai1, Wanqi Hou2, Yaxuan Sun3, Zhaolan Gao4, Shigong Zhu5, Zhaofeng Jiang6.
Abstract
Alzheimer's disease (AD) is characterized by a large number of amyloid-β (Aβ) deposits in the brain. Therefore, inhibiting Aβ aggregation or destabilizing preformed aggregates could be a promising therapeutic target for halting/slowing the progression of AD. Chitosan oligosaccharides (COS) have previously been reported to exhibit antioxidant and neuroprotective effects. Recent study shows that COS could markedly decrease oligomeric Aβ-induced neurotoxicity and oxidative stress in rat hippocampal neurons. However, the potential mechanism that COS reduce Aβ-mediated neurotoxicity remains unclear. In the present study, our findings from circular dichroism spectroscopy, transmission electron microscope and thioflavin T fluorescence assay suggested that COS act as an inhibitor of Aβ aggregation and this effect shows dose-dependency. Moreover, data from thioflavin T assay indicated that COS could significantly inhibit fibrils formation and disrupt preformed fibrils in a dose-dependent manner. Furthermore, the addition of COS attenuated Aβ1-42-induced neurotoxicity in rat cortical neurons. Taken together, our results demonstrated for the first time that COS could inhibit Aβ1-42 fibrils formation and disaggregate preformed fibrils, suggesting that COS may have anti-Aβ fibrillogenesis and fibril-destabilizing properties. These findings highlight the potential role of COS as novel therapeutic agents for the prevention and treatment of AD.Entities:
Keywords: Alzheimer’s disease; aggregation; amyloid-β peptide; chitosan oligosaccharides; neurotoxicity
Mesh:
Substances:
Year: 2015 PMID: 26006224 PMCID: PMC4463660 DOI: 10.3390/ijms160510526
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Circular Dichroism (CD) spectroscopy of Aβ42. Amyloid-β (Aβ) peptides were diluted with 10 mM phosphate buffer to a final concentration of 50 μM in each sample. (A) CD spectra of Aβ42 upon incubation were recorded in the UV region (190–240 nm) at 0, 3, 6, 12, 24 and 48 h respectively; (B) CD spectra of 50 μM Aβ42 were recorded in the UV region (190–240 nm) upon coincubation with 2.5 or 5.0 mg/mL chitosan oligosaccharides (COS) (when present) respectively for 48 h. Data were the average of six runs and represented as rainbow color curves after being smoothed.
Figure 2Effect of COS on Aβ aggregates visualized by Transmission Electron Microscopy (TEM). Representative TEM images of monomeric Aβ42 fractions soon after preparation (A) and fibrils formed by monomeric Aβ42 after 12 h (B), 24 h (C), and 48 h (D) of incubation at 37 °C (10 μM Aβ42, without agitation); Representative images of monomeric Aβ42 (10 μM) coincubated with 0.5 mg/mL (E) or 1.0 mg/mL COS (F) for 48 h at 37 °C were visualized by TEM. The scale bar (200 nm) is shown in the lower left of the images. Magnification: 80,000×.
Figure 3Effect of COS on Aβ fibrils formation. (A) Time-dependent thioflavin T (ThT) fluorescence intensity changes for 20 μM Aβ42 incubated with different concentration of COS (1.0 and 2.0 mg/mL respectively), as compared to 2.0 mg/mL COS or 20 μM Aβ42 alone; (B) Disaggregative effect of COS (1.0 and 2.0 mg/mL respectively) on preformed Aβ fibrils. Data were represented as mean ± SEM of three independent experiments. ** p < 0.01, * p < 0.05 vs. Aβ42 alone.
Figure 4Effect of COS on Aβ42-induced neurotoxicity in cortical neurons. (A) Neurons were treated with 5 μM Aβ42 with or without addition of 0.5 mg/mL COS for 48 h, the cell viability was determined by the MTT assay; (B) Representative graphs obtained by flow cytometry using double staining with Annexin V-FITC and PI; (C) The apoptotic incidence of rat cortical neurons exposed to 5 μM Aβ42 in the presence or absence of 0.5 mg/mL COS for 48 h. Results were expressed as the percentage of apoptotic cells that include neurons in early and late apoptotic phases. Data were expressed as means ± SEM of three independent experiments. ** p < 0.01 vs. Control, ## p < 0.01 vs. Aβ42 group.